Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.25
Bid: 8.00
Ask: 8.50
Change: 0.25 (3.13%)
Spread: 0.50 (6.25%)
Open: 8.25
High: 8.25
Low: 8.25
Prev. Close: 8.00
TEK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Belluscura Launches Passport Medical Device in US

3 Mar 2017 07:00

RNS Number : 4031Y
Tekcapital plc
03 March 2017
 



3 March 2017

Tekcapital plc

("Tekcapital" or the "Company")

 

BELLUSCURA LTD LAUNCHES PASSPORT® DISPOSABLE TROCAR IN USA

Tekcapital plc (AIM: TEK), an international provider of technology and intellectual property services, announces that Belluscura Ltd ("Belluscura") has launched Passport® in the United States.

Passport is a disposable trocar used in laparoscopic, or 'keyhole' surgery, and features the patented SmartTip™ technology, designed to be compatible with the Da Vinci®1 S and Si robotic surgical systems. Passport, with its unique seal, is used as the access point for the endoscope camera which allows the surgeon to visualise the procedure site. The SmartTip controls the cutting blade to prevent accidental deployment inside the patient and potential tissue damage.

It is estimated that more than 7.5 million laparoscopic procedures are performed annually2, with 2.8 million being performed in the US alone. Laparoscopic procedures continue to replace more invasive surgery because of the faster recovery, lower surgical headcount requirement and better training.3

 

Please click here for picture of Passport®

http://www.rns-pdf.londonstockexchange.com/rns/4031Y_-2017-3-2.pdf

 

Bob Rauker, Belluscura's CEO said: "The launch of this Passport trocar provides Belluscura with a presence in the surgical device field. Passport is the first of a family of trocars and cannulae that Belluscura will seek to launch over the coming years. Together, these will form a range of products to support surgeons in an array of specialties."

About Belluscura:

Belluscura Limited is a global medical device company founded in Oxford, England. Its mission is to make healthcare more affordable for patients and their providers by providing proprietary medical devices across a wide variety of treatment and diagnostic disciplines. Belluscura's products were originally developed by leading medical device companies or research centres, and with its unique business model it is able to offer these devices at affordable prices. To learn more about Belluscura please visit www.belluscura.com.

Tekcapital owns approximately 65% of the share capital of Belluscura.

 

 

For further information, please contact:

 

Tekcapital Plc

 

Clifford M. Gross, Ph.D.

info@tekcapital.com

 

Allenby Capital Limited (Nominated Adviser & Joint Broker)

 

+44 (0) 20 3328 5656

Jeremy Porter / Alex Brearley

 

 

 

Dowgate Capital Stockbrokers (Joint Broker)

+44 (0) 1293 517744

David Poutney / James Serjeant

 

 

 

Walbrook PR Ltd

+44 (0) 20 7933 8780

Paul Cornelius / Helen Cresswell / Sam Allen

tekcapital@walbrookpr.com

 

 

Tekcapital plc - The World's Largest University Network for Open Innovation

Tekcapital helps clients profit from new, university-developed intellectual properties. With its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a turn-key service to make it easy for clients to find and acquire the IP, analytics and technology transfer professionals they need to create a competitive advantage. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

LEI: 213800GOJTOV19FIFZ85

 

Note 1:

Da Vinci® is a registered trademark of Intuitive Surgical, Inc.

 

Note 2:

https://www.quora.com/On-average-how-many-laparoscopic-surgeries-are-performed-in-a-year-worldwide

 

Note 3:

http://www.transenterix.com/assets/TransEnterix-JPM-2016-PDF-No-Video- 2-MB.pdf

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASSWFMEFWSEID
Date   Source Headline
26th Oct 202111:05 amRNSSecond Price Monitoring Extn
26th Oct 202111:00 amRNSPrice Monitoring Extension
19th Oct 20218:00 amRNSLucyd Proposed IPO in the United States
19th Oct 20217:00 amRNSLucyd Update
14th Oct 202111:05 amRNSSecond Price Monitoring Extn
14th Oct 202111:00 amRNSPrice Monitoring Extension
14th Oct 20217:00 amRNSSalarius FDA Sodium Reduction Goals
8th Oct 20218:59 amRNSSaltMe Roll out in leading US Supermarket Chain
29th Sep 20212:17 pmRNSLucyd Distribution Growth
20th Sep 20214:41 pmRNSSecond Price Monitoring Extn
20th Sep 20214:36 pmRNSPrice Monitoring Extension
10th Sep 202111:30 amRNSNotification of Major Shareholding
31st Aug 20217:00 amRNSLucyd Update
24th Aug 20217:00 amRNSLucyd Non Executive Director Appointment
20th Aug 20219:05 amRNSSecond Price Monitoring Extn
20th Aug 20219:00 amRNSPrice Monitoring Extension
16th Aug 20217:00 amRNSRecord Half Year Results for period to 31 May 2021
5th Aug 20212:59 pmRNSHolding(s) in Company
5th Aug 20211:44 pmRNSNotification of Major Holding
5th Aug 20217:00 amRNSLucyd Appoints Non Executive Director
22nd Jul 20217:00 amRNSLucyd launches Crowdfund
5th Jul 202112:37 pmRNSNotification of Major Holdings
5th Jul 20217:00 amRNSLucyd Signs Canadian Distribution Agreement
1st Jul 20217:00 amRNSNotification of Investor Presentation
15th Jun 20212:05 pmRNSSecond Price Monitoring Extn
15th Jun 20212:00 pmRNSPrice Monitoring Extension
15th Jun 20217:00 amRNSGrant of Share Options
8th Jun 20217:00 amRNSNotice of Investor Presentation 8 June 2021
28th May 202110:40 amRNSResults of Annual General Meeting
28th May 20217:12 amRNSBelluscura First Day of Dealings on AIM
13th May 20217:00 amRNSNotice of AGM
10th May 20217:00 amRNSInvestor Presentation
7th May 20214:41 pmRNSSecond Price Monitoring Extn
7th May 20214:36 pmRNSPrice Monitoring Extension
7th May 20217:15 amRNSBelluscura Intention to Float on AIM
5th May 20217:00 amRNSPortfolio Company Update - Lucyd
4th May 20217:00 amRNSPortfolio Company Update - Guident
30th Apr 20217:00 amRNSFinal Results
1st Apr 20217:00 amRNSPortfolio Company Lucyd Update
31st Mar 20217:00 amRNSTotal Voting Rights
25th Mar 20217:00 amRNSNotification of Major Holdings
22nd Mar 20211:43 pmRNSNotification of Major Holdings
22nd Mar 20217:00 amRNSLucyd Signs Distribution Agreement
19th Mar 20214:21 pmRNSNotification of Major Holdings
19th Mar 202112:36 pmRNSNotification of Major Holdings
18th Mar 20219:05 amRNSSecond Price Monitoring Extn
18th Mar 20219:00 amRNSPrice Monitoring Extension
18th Mar 20217:00 amRNSPlacing to raise £3.8 million
11th Mar 20217:00 amRNSSalarius update
8th Mar 20217:00 amRNSBelluscura FDA Clearance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.